• Consensus Rating: Buy
  • Consensus Price Target: GBX 231
  • Forecasted Upside: 204.16 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 75.95
▼ -2.053 (-2.63%)

This chart shows the closing price for AGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ANGLE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGL

Analyst Price Target is GBX 231
▲ +204.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ANGLE in the last 3 months. The average price target is GBX 231, with a high forecast of GBX 231 and a low forecast of GBX 231. The average price target represents a 204.16% upside from the last price of GBX 75.95.

This chart shows the closing price for AGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in ANGLE.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/5/2022Berenberg BankReiterated RatingBuyGBX 231
5/23/2022Berenberg BankReiterated RatingBuyGBX 195
5/13/2022Berenberg BankReiterated RatingBuyGBX 195
4/28/2022Berenberg BankReiterated RatingBuyGBX 195
1/20/2022Berenberg BankInitiated CoverageBuyGBX 195
7/20/2020FinnCapReiterated RatingCorporate
6/22/2020FinnCapReiterated RatingCorporate
5/12/2020FinnCapReiterated RatingCorporate
4/28/2020FinnCapReiterated RatingCorporate
4/17/2020FinnCapReiterated RatingCorporate
3/31/2020FinnCapReiterated RatingCorporate
2/27/2020FinnCapReiterated RatingCorporate
1/30/2020FinnCapReiterated RatingCorporate
1/22/2020FinnCapReiterated RatingCorporate
10/30/2019FinnCapReiterated RatingCorporate
9/10/2019FinnCapReiterated RatingCorporate
7/31/2019FinnCapReiterated RatingCorporate
6/26/2019FinnCapReiterated RatingCorporate
5/31/2019FinnCapReiterated RatingCorporate
4/26/2019FinnCapReiterated RatingCorporate
4/18/2019FinnCapReiterated RatingCorporate
3/7/2019FinnCapReiterated RatingCorporate
2/25/2019FinnCapReiterated RatingCorporate
1/31/2019FinnCapReiterated RatingCorporate
1/11/2019FinnCapReiterated RatingCorporate
11/5/2018FinnCapReiterated RatingCorporate
10/25/2018FinnCapReiterated RatingCorporate
7/25/2018FinnCapReiterated RatingCorporate
6/26/2018FinnCapBoost TargetCorporateGBX 108 ➝ GBX 110
4/19/2018FinnCapReiterated RatingCorporateGBX 108
4/5/2018FinnCapReiterated RatingCorporate
3/26/2018FinnCapReiterated RatingCorporateGBX 108
2/12/2018FinnCapReiterated RatingCorporateGBX 108
1/31/2018FinnCapReiterated RatingCorporateGBX 108
1/8/2018FinnCapReiterated RatingCorporateGBX 108
11/21/2017FinnCapReiterated RatingCorporateGBX 108
10/23/2017FinnCapReiterated RatingCorporateGBX 108
10/9/2017FinnCapReiterated RatingCorporateGBX 108 ➝ GBX 100
9/11/2017FinnCapReiterated RatingCorporateGBX 100
9/5/2017FinnCapInitiated CoverageCorporateGBX 100
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/20/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
6/19/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ANGLE logo
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
Read More

Today's Range

Now: GBX 75.95
Low: 75.95
High: 77.75

50 Day Range

MA: GBX 86.68
Low: 69.50
High: 115.20

52 Week Range

Now: GBX 75.95
Low: 67
High: 163.75

Volume

154,024 shs

Average Volume

909,787 shs

Market Capitalization

£197.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ANGLE?

The following Wall Street analysts have issued reports on ANGLE in the last year: Berenberg Bank.
View the latest analyst ratings for AGL.

What is the current price target for ANGLE?

1 Wall Street analysts have set twelve-month price targets for ANGLE in the last year. Their average twelve-month price target is GBX 231, suggesting a possible upside of 204.2%. Berenberg Bank has the highest price target set, predicting AGL will reach GBX 231 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of GBX 231 for ANGLE in the next year.
View the latest price targets for AGL.

What is the current consensus analyst rating for ANGLE?

ANGLE currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGL will outperform the market and that investors should add to their positions of ANGLE.
View the latest ratings for AGL.

What other companies compete with ANGLE?

How do I contact ANGLE's investor relations team?

ANGLE's physical mailing address is The Surrey Research Park 3 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company's listed phone number is +44-1483-685830. The official website for ANGLE is www.angleplc.com. Learn More about contacing ANGLE investor relations.